Comparative Study on Biodistribution of161Tb-Labeled Radioimmunoconjugate and Radiochemical Forms of Terbium-161 potentially present in vivo (EANM 2026) - Sep 29, 2026 - Abstract #EP-0202; "Materials and The experiment compared the biodistribution of 161Tb-labeled anti-VEGFR2 monoclonal antibody ramucirumab conjugated with DOTA, the complex of DOTA with terbium-161, and free terbium-161 in mice... According to the obtained biodistribution data, the DOTA-complex of terbium-161, potentially released from radiolabeled biomolecules such as radioimmunoconjugates, is unlikely to pose a risk in terms of unwanted exposure of non-target tissues. The complex exhibits rapid excretion and no significant tissue accumulation. In contrast, long-term accumulation of the free cationic form of terbium-161 in the bone can be an undesirable complication."
Preclinical
|
|
F. Trejtnar 1; P. Barta 1; N. Mehdizadeh 1; M. Vlk 2; J. Kozempel 2; M. Skalova 2; T. Janska 2
|